105P US real-world treatment patterns and outcomes of metastatic nonsquamous non-small cell lung cancer (mNSQ NSCLC) patients (pts) after progression on standard of care (SOC)

Abstract

The SOC for mNSQ NSCLC pts with no targetable genetic alterations is immunotherapy (IO) or platinum-based chemotherapy (CT) alone in 1L followed by the other in 2L or platinum-based CT and IO in 1L. SOC for pts with targetable genetic alterations (EGFR, ALK, ROS1) is one or more lines of tyrosine kinase inhibitors (TKIs). Data on optimal subsequent treatment after progression(s) on SOC are scarce.